Page last updated: 2024-11-12

epoxomicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11226684
CHEBI ID42265
SCHEMBL ID73907
MeSH IDM0211247

Synonyms (32)

Synonym
134381-21-8
epoxomicin ,
bu-4061t
l-threoninamide, n-acetyl-n-methyl-l-isoleucyl-l-isoleucyl-n-((1s)-3-methyl-1-(((2r)-2-methyl-2-oxiranyl)carbonyl)butyl)-
n-acetyl-n-methyl-l-isoleucyl-l-isoleucyl-n-((1s)-3-methyl-1-(((2r)-2-methyl-2-oxiranyl)carbonyl)butyl)-l-threoninamide
n-acetyl-n-methyl-l-isoleucyl-l-isoleucyl-n-{(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-l-threoninamide
epoxomycin
chebi:42265 ,
n-acetyl-n-methyl-l-isoleucyl-l-isoleucyl-n-(3-methyl-1-((2-methyloxiranyl)carbonyl)butyl)-l-threoninamide
y0900i3u8u ,
bu 4061t
unii-y0900i3u8u
epoxomicin [mi]
SCHEMBL73907
CS-3998
DTXSID5044073
Y-100034
(2r,3s)-2-[acetyl(methyl)amino]-n-[(2s,3s)-1-{[(2s,3r)-3-hydroxy-1-({(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}amino)-1-oxobutan-2-yl]amino}-3-methyl-1-oxopentan-2-yl]-3-methylpentanamide
HY-13821
AKOS025396426
(2s,3s)-n-[(1s,2r)-2-hydroxy-1-{[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}propyl]-3-methyl-2-[(2s,3s)-3-methyl-2-(n-methylacetamido)pentanamido]pentanamide
epoxomicin, >=95% (hplc), solid
NCGC00485955-01
Q5383826
EX-A1663
mfcd03791061
bu-4061t,aids010837
BCP13740
(2s,3s)-2-[[(2s,3s)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino]-n-[(2s,3r)-3-hydroxy-1-[[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]-3-methylpentanamide
MS-30118
NCGC00389337-01
epoxomicin solution

Research Excerpts

Treatment

Epoxomicin treatment also rescued intercellular transfer of Neurobiotin to levels similar to those in cells expressing the wild type protein. Treatment decreased the levels of the majority of intracellular peptides, consistent with inhibition of the proteasome beta-2 and beta-5 subunits.

ExcerptReferenceRelevance
"Epoxomicin treatment also rescued intercellular transfer of Neurobiotin to levels similar to those in cells expressing the wild type protein."( A connexin50 mutant, CX50fs, that causes cataracts is unstable, but is rescued by a proteasomal inhibitor.
Berthoud, VM; Beyer, EC; Minogue, PJ, 2013
)
1.11
"Epoxomicin treatment decreased the levels of the majority of intracellular peptides, consistent with inhibition of the proteasome beta-2 and beta-5 subunits."( Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.
Castro, LM; Ferro, ES; Fricker, LD; Gelman, JS; Gozzo, FC, 2012
)
1.33
"The treatment with epoxomicin increases, in wild type (WT) cultures, the pro-apoptotic Bax/Bcl-2 ratio, the phosphorylation of tau, and the levels of chaperones heat-shock protein 70 and C-terminal Hsc-interacting protein, but none of these effects took place in epoxomicin-treated PK-KO cultures."( Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Casarejos, MJ; Castaño, JG; García de Yébenes, J; Gómez, A; Mena, MA; Perucho, J; Rodriguez-Navarro, JA; Solano, RM, 2009
)
0.67

Toxicity

ExcerptReferenceRelevance
"Testing the effects of compounds on the viability of cells grown in culture is widely used as a predictor of potential toxic effects in whole animals."( Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death.
Moravec, RA; Niles, AL; Riss, TL, 2011
)
0.37
" Using siRNA technology, we show here that MCPIP1 expression contributes to the toxic properties of MG-132 in HeLa cells."( MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB.
Dziendziel, M; Jura, J; Skalniak, L, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
proteasome inhibitorA drug that blocks the action of proteasomes, cellular complexes that break down proteins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
morpholinesAny compound containing morpholine as part of its structure.
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Cathepsin BHomo sapiens (human)IC50 (µMol)120.00000.00021.845310.0000AID264538
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.505710.0000AID265542
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.497310.0000AID265542
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)1.25000.00060.73766.3700AID264537; AID734278
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.498810.0000AID265542
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.504610.0000AID265542
Cathepsin SHomo sapiens (human)IC50 (µMol)25.00000.00021.319110.0000AID264539
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)0.02560.00050.939410.0000AID264535; AID265543; AID734279
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)0.57000.00131.39067.9540AID264536; AID265542
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.506510.0000AID265542
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.505710.0000AID265542
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.98000.00010.507510.0000AID265542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
toll-like receptor signaling pathwayCathepsin SHomo sapiens (human)
adaptive immune responseCathepsin SHomo sapiens (human)
proteolysisCathepsin SHomo sapiens (human)
apoptotic processCathepsin SHomo sapiens (human)
response to acidic pHCathepsin SHomo sapiens (human)
protein processingCathepsin SHomo sapiens (human)
antigen processing and presentationCathepsin SHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin SHomo sapiens (human)
extracellular matrix disassemblyCathepsin SHomo sapiens (human)
collagen catabolic processCathepsin SHomo sapiens (human)
basement membrane disassemblyCathepsin SHomo sapiens (human)
antigen processing and presentation of peptide antigenCathepsin SHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin SHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin SHomo sapiens (human)
positive regulation of cation channel activityCathepsin SHomo sapiens (human)
positive regulation of peptidase activityCathepsin SHomo sapiens (human)
immune responseCathepsin SHomo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin SHomo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
fibronectin bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin SHomo sapiens (human)
serine-type endopeptidase activityCathepsin SHomo sapiens (human)
collagen bindingCathepsin SHomo sapiens (human)
laminin bindingCathepsin SHomo sapiens (human)
proteoglycan bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin SHomo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
late endosomeCathepsin SHomo sapiens (human)
endolysosome lumenCathepsin SHomo sapiens (human)
lysosomal lumenCathepsin SHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin SHomo sapiens (human)
phagocytic vesicleCathepsin SHomo sapiens (human)
collagen-containing extracellular matrixCathepsin SHomo sapiens (human)
tertiary granule lumenCathepsin SHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID734278Inhibition of postacid activity of 20s proteasome beta-1 subunit in HEK293 cells using Z-nLPnLD-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta1 assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
AID155425Inhibitory activity against papain at concentration up to 50 uM; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID426859Inhibition of chymotrypsin trypsin-like activity of proteasome from human LCL after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID565708Antimicrobial activity against gametocyte stage of Plasmodium falciparum 3D7 assessed as reduction in parasite count at 1 uM after 24 hrs by Giemsa staining2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID565707Antimicrobial activity against gametocyte stage of Plasmodium falciparum 3D7 assessed as reduction in parasite count at 100 nM after 24 hrs by Giemsa staining2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID1595608Cytotoxicity against human RPMI8226/Cfzr cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID265543Inhibition of chymotrypsin like activity of proteasome2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors.
AID264544Solubility in PBS at pH 7.42006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID511962Inhibition of chymotrypsin-like activity of 20S proteasome beta2 in human LCL cells after 12 hrs2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors.
AID774658Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID363817Inhibition of trypsin like 20S proteasome activity in lymphoblastoid cells2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors.
AID511963Inhibition of PGPH catalytic activity of 20S proteasome beta2 in human LCL cells after 12 hrs2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors.
AID426863Inhibition of post acidic activity of proteasome from human PBMC after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID683699Antimalarial activity against liver stages of Plasmodium yoelii yoelii2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID46352Inhibitory activity against calpain at concentration up to 50 uM; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID562310Antimicrobial activity against gametocyte stage of Plasmodium falciparum 3D7 after 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID418010Inhibition of trypsin-like activity of 20S proteasome beta 2 subunit by fluorimeter2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
New cyclic peptide proteasome inhibitors.
AID426862Inhibition of chymotrypsin trypsin-like activity of proteasome from human PBMC after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID264537Inhibition of post glutamyl peptide hydrolase-like proteasome activity of human 20S proteasome2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID562309Antimicrobial activity against asexual stage of Plasmodium falciparum 3D7 assessed as reduction in parasite count at 1uM after 24 hrs by Giemsa staining2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID264543Stability in human plasma after 120 mins2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID233195Inhibition of the PGPH-like activity1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.
AID562313Cytotoxicity against mouse 3T3 cells assessed as viable cells at 1 uM by MTS assay in presence of 10% fetal calf serum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID264541Ratio of IC50 for PC3 cells to IC50 for chymotrypsin-like proteasome activity of 20S proteasome2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID1394970Gametocytocidal activity against Plasmodium falciparum NF54 HGL gametocytes assessed as inhibition of parasite viability after 72 hrs by ONE-Glo reagent based luminescence assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog
AID1421918Gametocytocidal activity against synchronized Plasmodium falciparum NF54 mature stage 5 gametocytes after 48 hrs by ATP bioluminescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID317821Inhibition of chymotrypsin-like activity of 20S proteasome2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Vinyl ester-based cyclic peptide proteasome inhibitors.
AID264536Inhibition of trypsin-like proteasome activity of human 20S proteasome2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID264540Antiproliferative activity against human PC3 cell line2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID213363Inhibitory activity against trypsin at concentration up to 50 uM; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID1595607Cytotoxicity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID233197Inhibition of the trypsin-like activity1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.
AID264535Inhibition of chymotrypsin-like proteasome activity of human 20S proteasome2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID562312Cytotoxicity against human A549 cells assessed as viable cells at 1 uM by MTS assay in presence of 10% fetal calf serum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID1882258Inhibition of proteasome (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1179576Inhibition of chymotrypsin-like activity of human 20S immunoproteasome using Suc-LLVY-AMC as substrate at 1 uM after 90 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID640519Inhibition of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 0.1 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID3031Inhibitory activity against 20S proteosome1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID709183Antimalarial activity against Plasmodium falciparum stage 3 to 5 gametocytes2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID711001Inhibition of Saccharomyces cerevisiae chymotrypsin-like activity of 20S proteasome using Suc-LLVY-AMC as substrate preincubated for 15 mins by fluorescence spectrophotometric analysis2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
AID671278Irreversible inhibition of chymotryptic-like of purified human 20S proteasome assessed as Suc-LLVY-AMC substrate at 1 uM measured after drug washout2012Journal of natural products, May-25, Volume: 75, Issue:5
Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome.
AID233196Inhibition of the chymotrypsin-like activity1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.
AID317823Inhibition of post acidic active site of 20S proteasome2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Vinyl ester-based cyclic peptide proteasome inhibitors.
AID317822Inhibition of trypsin-like activity of 20S proteasome2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Vinyl ester-based cyclic peptide proteasome inhibitors.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID640522Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID52457Inhibitory activity against chymotrypsin at concentration up to 50 uM; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID734279Inhibition of chymotrypsin-like activity of proteasome beta-5 subunit in HEK293 cells using Suc-LLVY-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta5 assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
AID562308Antimicrobial activity against asexual stage of Plasmodium falciparum 3D7 assessed as reduction in parasite count at 100 nM after 24 hrs by Giemsa staining2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID640520Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID426858Inhibition of trypsin-like activity of proteasome from human LCL after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID426861Inhibition of trypsin-like activity of proteasome from human PBMC after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID1274390Antimalarial activity against 4th to 5th gametocyte stage of Plasmodium falciparum 3D7elo1-pfs16-CBG99 assessed as inhibition of gametocyte viability by luciferase reporter gene assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID774663Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID640446Inhibition of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 1 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID226665Antiproliferative activity of the compound1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.
AID264539Inhibition of cathepsin S2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID426860Inhibition of post acidic activity of proteasome from human LCL after 30 mins by fluorimetry2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
AID1394968Gametocytocidal activity against Plasmodium falciparum 3D7 elo1-pfs16-CBG99 late-stage (4 to 5) gametocytes assessed as inhibition of parasite viability after 72 hrs by luciferase reporter assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog
AID511961Inhibition of trypsin-like activity of 20S proteasome beta2 in human LCL cells after 12 hrs2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors.
AID774661Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID418009Inhibition of chymotrypsin-like activity of 20S proteasome beta 5 subunit by fluorimeter2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
New cyclic peptide proteasome inhibitors.
AID50107Inhibitory activity against cathepsin at concentration up to 50 uM; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
AID1595609Selectivity ratio of IC50 for human RPMI8226/Cfzr cells to IC50 for human RPMI8226 cells2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID265542Inhibition of trypsin like activity of proteasome2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors.
AID264538Inhibition of cathepsin B2006Journal of medicinal chemistry, May-18, Volume: 49, Issue:10
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
AID363818Inhibition of chymotrypsin like 20S proteasome activity in lymphoblastoid cells2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors.
AID363819Inhibition of caspase like 20S proteasome activity in lymphoblastoid cells2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors.
AID418011Inhibition of caspase-like activity of 20S proteasome beta 1 subunit by fluorimeter2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
New cyclic peptide proteasome inhibitors.
AID562311Antimicrobial activity against asexual stage of Plasmodium falciparum 3D7 after 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID640521Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (247)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (1.62)18.2507
2000's114 (46.15)29.6817
2010's116 (46.96)24.3611
2020's13 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.28 (24.57)
Research Supply Index5.53 (2.92)
Research Growth Index6.01 (4.65)
Search Engine Demand Index51.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews12 (4.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other239 (95.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]